Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Amphastar Pharmaceuticals, Inc. (AMPH)

35.34   0.54 (1.55%) 05-16 01:20
Open: 35.09 Pre. Close: 34.8
High: 35.43 Low: 34.19
Volume: 569,060 Market Cap: 1,726(M)
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 35.48 - 35.62 35.62 - 35.76
Low: 33.84 - 33.99 33.99 - 34.14
Close: 35.08 - 35.33 35.33 - 35.57

Technical analysis

as of: 2022-05-13 4:36:17 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 45.98     One year: 51.92
Support: Support1: 31.13    Support2: 25.9
Resistance: Resistance1: 39.37    Resistance2: 44.45
Pivot: 34.73
Moving Average: MA(5): 33.77     MA(20): 35.67
MA(100): 30.52     MA(250): 24.1
MACD: MACD(12,26): -0.8     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 42.3     %D(3): 31.4
RSI: RSI(14): 49.7
52-week: High: 44.45  Low: 17.55
Average Vol(K): 3-Month: 496 (K)  10-Days: 504 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AMPH ] has closed below upper band by 38.8%. Bollinger Bands are 1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 13 May 2022
Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio - Seeking Alpha

Thu, 12 May 2022
7 Safe Small-Cap Stocks to Buy Now - Nasdaq

Thu, 12 May 2022
Narcotics Control thwarts attempt to smuggle over 11mln amphetamine pills, 24.8kgs of hashish in Saudi Arabia - ZAWYA

Wed, 11 May 2022
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily

Tue, 10 May 2022
Amphastar Pharmaceuticals (AMPH) Q1 2022 Earnings Call Transcript - The Motley Fool

Mon, 09 May 2022
Amphastar: Q1 Earnings Snapshot - Torrington Register Citizen

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 49 (M)
Shares Float 37 (M)
% Held by Insiders 22.7 (%)
% Held by Institutions 61.6 (%)
Shares Short 2,040 (K)
Shares Short P.Month 2,020 (K)

Stock Financials

EPS 1.25
EPS Est Next Qtl 0
EPS Est This Year 0.27
EPS Est Next Year 0.67
Book Value (p.s.) 9.34
Profit Margin (%) 14.1
Operating Margin (%) 16.3
Return on Assets (ttm) 6.8
Return on Equity (ttm) 14.1
Qtrly Rev. Growth 26
Gross Profit (p.s.) 4.09
Sales Per Share 8.96
EBITDA (p.s.) 1.94
Qtrly Earnings Growth 0
Operating Cash Flow 98 (M)
Levered Free Cash Flow 57 (M)

Stock Valuations

PE Ratio 28.27
PEG Ratio 0.8
Price to Book value 3.78
Price to Sales 3.94
Price to Cash Flow 17.6

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.